It was found to be efficacious in trastuzumab-insensitive models such as HER2 overexpressing breast cancer cell lines [55] and in HER2-expressing lung, ovarian, and gastric carcinoma cell lines [14]. Here, ERBB2 is linked to gastric carcinoma.